What is the appropriate initial dose of insulin glargine for an adult patient with renal impairment when the patient's weight is unknown?

Initial Dosing of Insulin Glargine in Renal Impairment

For an adult patient with renal impairment and unknown weight, start insulin glargine at 10 units once daily, then titrate conservatively with close glucose monitoring to avoid hypoglycemia. 1

Dosing Algorithm

For Type 2 Diabetes (Insulin-Naïve)

The FDA-approved starting dose is 0.2 units/kg or up to 10 units once daily 1. When weight is unknown:

• Start with 10 units once daily as the default conservative dose
• This approach is supported by real-world evidence showing a median starting dose of 10 units in CKD patients 2
• Administer at the same time each day (any time, but consistent)

For Type 1 Diabetes

• Start at approximately one-third of total daily insulin requirements
• Must be combined with short-acting insulin for meal coverage 1

Critical Considerations in Renal Impairment

Titrate conservatively and increase glucose monitoring frequency 3. The ADA/KDIGO consensus specifically states to "initiate and titrate conservatively to avoid hypoglycemia" in patients with eGFR <45 mL/min/1.73 m² 3.

Why Conservative Dosing Matters

• Insulin clearance decreases as renal function declines, increasing hypoglycemia risk
• The long-acting effect of glargine may delay recovery from hypoglycemia 1
• Real-world data shows hypoglycemia rates increase slightly with declining eGFR (0.01%/year in early CKD to 0.04%/year in advanced stages) 4

Titration Strategy

• Adjust dose based on fasting plasma glucose targets (typically 90-130 mg/dL)
• Use a prespecified algorithm with small incremental changes 2
• Monitor more frequently than in patients without renal impairment
• Dosage adjustments should only be made under medical supervision 1

Safety Profile in CKD

Real-world evidence demonstrates glargine is safe across all CKD stages:

• Low severe hypoglycemia rates even in advanced CKD 2, 4
• No significant weight changes 2, 5
• Effective glycemic control with HbA1c reductions of approximately 1.2% 2
• Widely used in CKD Stage 5, though with distinct patient profiles (lower doses may be needed) 4

Common Pitfalls to Avoid

1. Do not use weight-based dosing blindly - When weight is unknown and renal impairment exists, default to the conservative 10-unit starting dose rather than estimating weight
2. Do not skip the conservative titration - Aggressive up-titration increases hypoglycemia risk in renal impairment
3. Do not forget to adjust other medications - Many oral antidiabetic drugs require dose reduction or discontinuation in renal impairment 3, 6
4. Monitor for delayed hypoglycemia - The 24-hour duration of glargine means hypoglycemia can occur at any time, not just at peak effect

Administration Details

• Subcutaneous injection into abdomen, thigh, or deltoid
• Rotate injection sites within the same region
• Do not dilute, mix with other insulins, or administer IV
• Do not use in insulin pumps 1